**Ovary, Fallopian Tube and Primary Peritoneal Carcinoma**

**Histopathology Reporting Guide**

<table>
<thead>
<tr>
<th>Family/Last name</th>
<th>Date of birth</th>
<th>DD – MM – YYYY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Given name(s)</th>
<th>Date of request</th>
<th>Accession/Laboratory number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DD – MM – YYYY</td>
<td></td>
</tr>
</tbody>
</table>

Patient identifiers

Elements in **black text** are REQUIRED. Elements in **grey text** are RECOMMENDED.

**GENETIC STATUS**

- BRCA1
- BRCA2
- Lynch syndrome
- Other

**PRIOR CHEMOTHERAPY**

- No chemotherapy administered
- Prior chemotherapy administered

**SPECIMEN TYPE** (select all that apply)

- Right ovary
- Left ovary
- Right ovarian cystectomy
- Left ovarian cystectomy
- Right fallopian tube
- Left fallopian tube
- Uterus
- Cervix
- Omentum
- Peritoneal biopsies
- Peritoneal washings/ascitic fluid
- Lymph nodes (specify site/s)

**MACROSCOPIC TUMOUR SITE** (select all that apply)

- Left ovary
- Right ovary
- Left fallopian tube
  - Fimbrial
  - Non fimbrial
- Right fallopian tube
  - Fimbrial
  - Non fimbrial
- Peritoneum
- Other (specify)

**MACROSCOPIC DESCRIPTION OF OMENTUM**

*Required only if omentum submitted*

- Omentum dimensions
  - mm x mm x mm

- Omental involvement
  - Involved
  - Not involved

**TUMOUR DIMENSIONS**

- mm x mm x mm

(Note: If separate tumours specify dimensions for each site)

**SPECIMEN INTEGRITY**

*Required only if ovary(ies)/fallopian tube(s) are submitted*

Right ovary

- Ovarian capsule intact
- Ovarian capsule ruptured
- Tumour on surface
- Fragmented specimen
- Other

Left ovary

- Ovarian capsule intact
- Ovarian capsule ruptured
- Tumour on surface
- Fragmented specimen
- Other

Right fallopian tube

- Serosa intact
- Serosa ruptured
- Tumour on serosal surface
- Fragmented specimen
- Other

Left fallopian tube

- Serosa intact
- Serosa ruptured
- Tumour on serosal surface
- Fragmented specimen
- Other

**BLOCK IDENTIFICATION KEY**

(List overleaf or separately with an indication of the nature and origin of all tissue blocks)
HISTOLOGICAL TUMOUR TYPE

PATTERN OF INVASION (For mucinous carcinomas only)

- Expansile
- Infiltrative/destructive

CARCINOSARCOMA SUBTYPES

- Epithelial
  - Percentage: %
  - List subtypes

- Sarcomatous
  - Percentage: %
  - Type: Heterologous, Homologous
  - List subtypes

TUMOUR GRADE

Note: If chemotherapy has been administered the grading may need to be based on the pre-chemotherapy biopsy.

Serous carcinomas:
- Low grade
- High grade

Endometrioid carcinomas:
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- GX: Cannot be graded

Clear cell carcinomas:
- High grade

Undifferentiated carcinomas:
- High grade

Carcinosarcomas:
- High grade

Mucinous carcinomas:
- G1: Well differentiated
- G2: Moderately differentiated
- G3: Poorly differentiated
- GX: Cannot be graded

Nodules of anaplastic carcinoma
(For mucinous tumours only)
- Not identified
- Present

BORDERLINE TUMOUR

- Present
- Absent

Histological tumour type

BORDERLINE TUMOUR (cont.)

Special features

- Micropapillary architecture for serous borderline tumour (at least 5 mm in one dimension)
  - Absent
  - Present

- Microinvasion (upper limit 5 mm)
  - Absent
  - Present

- Intraepithelial carcinoma for mucinous borderline tumour
  - Absent
  - Present

Implants for serous & seromucinous borderline tumour

- Non-invasive implants
  - Not identified
  - Present

- Invasive implants/Extra-ovarian low grade serous carcinoma
  - Not identified
  - Present

- Indeterminate
  - Not identified
  - Present

SEROUS TUBAL INTRAEPITHELIAL CARCINOMA (STIC)

Required only if fallopian tube(s) are submitted and applicable to high grade serous carcinoma only

Right FT
- Present - fimbrial
- Present - non-fimbrial
- Not identified
- Cannot be assessed

Left FT
- Present - fimbrial
- Present - non-fimbrial
- Not identified
- Cannot be assessed

HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT

Right ovary
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Left ovary
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Right ovarian capsule/surface
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Left ovarian capsule/surface
- Not involved
- Involved
- Cannot be assessed
- Not applicable

Right fallopian tube
- Not involved
- Involved
- Cannot be assessed
- Not applicable
### HISTOLOGICAL SITES OF TUMOUR INVOLVEMENT (Cont.)

<table>
<thead>
<tr>
<th>Site</th>
<th>Involved</th>
<th>Not involved</th>
<th>Cannot be assessed</th>
<th>Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left fallopian tube</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uterus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omentum</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peritoneum (including uterine serosa)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other involved organs(s)/sites(s) (specify)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### PERITONEAL CYTOLOGY

- Negative
- Positive
- Indeterminate
- Not received

### RESPONSE TO NEOADJUVANT THERAPY

- No prior treatment
- Cannot be assessed

### LYMPH NODE STATUS (cont.)

#### Regional

- Right pelvic
  - Number of lymph nodes examined**
  - Number of positive lymph nodes**
- Para-aortic
  - Number of lymph nodes examined**
  - Number of positive lymph nodes**
- Maximum dimension of largest deposit in regional node
  - **mm**

#### Non-regional

- Site 1:
  - Number of lymph nodes examined**
  - Number of positive lymph nodes**
- Site 2:
  - Number of lymph nodes examined**
  - Number of positive lymph nodes**

### COEXISTENT PATHOLOGY

- Endometriosis (specify sites)
- Other (specify)

### ANCILLARY STUDIES

- Immunohistochemical markers
- Molecular data

**Note:** In some cases it may not be possible to record the actual number of nodes due to fragmentation of the specimen.
## Site of primary tumour

- Primary tumour, ovary (OV)
- Primary tumour, fallopian tube (FT)
- Primary tumour, peritoneum (P)
- Undesignated: site of primary tumour cannot be assessed (X)

## Stage

### I Tumour is confined to ovaries or fallopian tube(s)

- **IA** Tumour limited to 1 ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings

- **IB** Tumour limited to both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings

- **IC** Tumour limited to 1 or both ovaries or fallopian tubes, with any of the following:
  - **IC1** Surgical spill
  - **IC2** Capsule ruptured before surgery or tumour on ovarian or fallopian tube surface
  - **IC3** Malignant cells in the ascites or peritoneal washings

### II Tumour involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancer

- **IIA** Extension and/or implants on uterus and/or fallopian tubes and/or ovaries

- **IIB** Extension to other pelvic intraperitoneal tissues

### III Tumour involves 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes

- **IIIA1** Positive retroperitoneal lymph nodes only (cytologically or histologically proven):
  - **IIIA1(i)** Metastasis up to 10mm in greatest dimension
  - **IIIA1(ii)** Metastasis more than 10mm in greatest dimension

- **IIIA2** Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes

- **IIIB** Macroscopic peritoneal metastasis beyond the pelvis up to 2cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes

- **IIIC** Macroscopic peritoneal metastasis beyond the pelvis more than 2cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)

### IV Distant metastasis excluding peritoneal metastases

- **IVA** Pleural effusion with positive cytology

- **IVB** Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)